intranasal delivery raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-30 and is reviewed periodically as new material appears.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Zverev maintained his top 5 ranking throughout the year. However, he still did not deliver any high-calibre results at the major tournaments. He was upset at the Australian Open by reigning Next Gen Finals champion and No. 59 Chung Hyeon in five sets in the third round. Zverev stated that issues at majors were "definitely not physical" when asked if his problems were physical or mental, and also attribute this lack of success to the extra pressure he was putting on himself at these events. Zverev did not reach his first final of the year until early April at the Miami Masters. Despite taking the first set of the final, he finished runner-up to American John Isner, who had never previously won a Masters title. Zverev continued his Masters success into the clay-court season, reaching the semifinals at the Monte Carlo Masters, winning his third career Masters title at the Madrid Open, and making the final at the Rome Masters. In Madrid, he defeated Dominic Thiem in the final to become the only active player outside of the Big Four to have won three Masters titles. He came close to winning back-to-back Masters events, going up a break in the third set against Nadal at the Italian Open. However, Nadal was able to recover and win the final five games of the match after a rain delay. Zverev had also defended his title at the Bavarian International Tennis Championships in his only other French Open tune-up to help build up a 13 match win streak that lasted until the Italian Open final.
Ancrod (also known as Viprinex), a serine protease derived from the venom of the Malayan pit vipers, was under development for the treatment of acute ischemic stroke; after Knoll was acquired by Abbott, Abbott licensed the rights to ancrod to Empire Pharmaceuticals, a startup that included a Knoll employee who had worked on ancrod. In 2004 Empire was acquired by Neurobiological Technologies (NTI). Ancrod failed in a Phase III clinical trial in 2008, which led to the demise of NTI.
== Structure == The prostate is an exocrine gland of the male reproductive system. In adults, it is about the size of a walnut, and has an average weight of about 11 grams (0.39 oz), usually ranging between 7 and 16 grams (0.25–0.56 oz). The prostate is located in the pelvis. It sits below the urinary bladder and surrounds the urethra. The part of the urethra passing through it is called the prostatic urethra, which joins with the two ejaculatory ducts. The prostate is covered in a surface called the prostatic capsule or prostatic fascia. The internal structure of the prostate has been described using both lobes and zones. Because of the variation in descriptions and definitions of lobes, the zone classification is used more predominantly. The prostate has been described as consisting of three or four zones. Zones are more typically able to be seen on histology, or in medical imaging, such as ultrasound or MRI.
== Cultivation == The sacred lotus grows in water about 2.5 m (8 ft) to 30 cm (12 in) deep. In colder climates, a deeper water level protects the tubers more effectively, and improves growth and flowering. The sacred lotus germinates at temperatures above 13 °C (55 °F). Most varieties are not naturally cold-hardy, but may readily adapt to living outdoors year-round in USDA hardiness zones 6 through 11 (with some growers having success in zones as low as 4 or 5); the higher the zone's number, the greater the adaptability of the plants. In the growing season (from April to September in the northern hemisphere), the average daytime temperature needed is 23 to 27 °C (73 to 81 °F). In regions with low light levels in winter, the sacred lotus has a period of dormancy. The tubers are not cold-resistant if removed from water and exposed to the air; but when kept underwater in soil, the energy-rich tubers can overwinter temperatures below 0 °C (32 °F). If the plants are taken out of the water for wintertime storage (mostly in exceptionally cold climates), the tubers and roots must be stored in a stable, frost-free location, such as a garage, preferably in a cardboard box or container filled completely with vermiculite or perlite. Care must be taken to fully insulate the tubers.
Sources: en.wikipedia.org
On 26 February, after setting 737 of Kuwait's oil wells on fire, Iraqi troops began retreating. A long convoy of retreating Iraqi troops formed along the main Iraq–Kuwait highway. This convoy was bombed so extensively by coalition air forces that it came to be known as the Highway of Death. Thousands of Iraqi troops were killed. American, British, and French forces continued to pursue retreating Iraqi forces over the border and back into Iraq, eventually moving to within 240 km (150 mi) of Baghdad, before withdrawing back to Iraq's border with Kuwait and Saudi Arabia.
== Y == Ada Yonath (1939–2026). Israeli crystallographer at the Weizmann Institute of Science, best known for her pioneering work on the structure of the ribosome. Nobel Prize in Chemistry (2009). Member Natl. Acad. Sci. USA. Frank Young FRS (1908–1988). British biochemist at Cambridge University, where he was Sir William Dunn Professor for many years. William John Young (1878–1942). British biochemist at the University of Melbourne who worked on fermenting enzymes in yeast extract, and discovered “Harden–Young ester” (fructose 1,6-bisphosphate).
An identical band was found doing the reverse order of the detection; meaning Myc antibody was immunoprecipitated then followed by blotting with the HA antibody. So, the method had proven to work that photo-Met could cross-link proteins, but the physiological implications of this cross-linking has yet to be determined.
Sources: en.wikipedia.org
LifeAct is a 17 amino acid recombinant peptide that stains filamentous actin (F-actin) structures of eukaryotic living or fixed cells. There are several types and combinations of LifeAct that can be utilized depending on the cell type, protocol, and purpose of the analysis.
== Cross-linking with hemoglobin-albumin == Disuccinimidyl suberate's reactivity toward primary amines allows it to serve as a cross-linking agent for proteins, without toxic side-products and forming peptide bonds with the lysine residues in a single step. In a study on blood substitutes, DSS was shown to cross-link Hemoglobin intramolecularly, yielding a relatively stable protein (polymerized Hb or polyHb), whose oxygen affinity was almost halved compared to that of native Hb. This was shown to be reversed when Hemoglobin was copolymerized with bovine serum albumin (BSA), showing very little change in auto-oxidation and oxygen affinity compared to the native Hb.
Several forms (vitamers) of vitamin D exist, with the two major forms being vitamin D2 (ergocalciferol), and vitamin D3 (cholecalciferol). The common-use term "vitamin D" refers to both D2 and D3, which were chemically characterized, respectively, in 1931 and 1935. Vitamin D3 was shown to result from the ultraviolet irradiation of 7-dehydrocholesterol. Although a chemical nomenclature for vitamin D forms was recommended in 1981, alternative names remain commonly used. Chemically, the various forms of vitamin D are secosteroids, meaning that one of the bonds in the steroid rings is broken. The structural difference between vitamin D2 and vitamin D3 lies in the side chain: vitamin D2 has a double bond between carbons 22 and 23, and a methyl group on carbon 24. Vitamin D analogues have also been synthesized. US dietary guides generally assume that all of a person's vitamin D is taken orally, given the potential for insufficient sunlight exposure due to urban living, cultural choices for the amount of clothing worn when outdoors, and use of sunscreen because of concerns about safe levels of sunlight exposure, including the risk of skin cancer.
A drug-related wider conflict broke out in 2024. In 2012, the US sent DEA agents to Honduras to assist security forces in counter-narcotic operations. Honduras has been a major stop for drug traffickers, who use small planes and landing strips hidden throughout the country to transport drugs. The DEA, working with other US agencies such as the State Department, the CBP, and Joint Task Force-Bravo, assisted Honduran troops in conducting raids on traffickers' sites of operation.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.